Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition

Gabrielle S. Wong(Dana-Farber Cancer Institute), Adam J. Bass(Dana-Farber Cancer Institute), Christopher Szeto(La Trobe University), Francesco Graziano(Ospedale Vincenzo Cervello), Kwok‐Kin Wong(NYU Langone Health), David Xu(University of Chicago Medical Center), Anil K. Rustgi(Columbia University Irving Medical Center), Shaunt Fereshetian(Broad Institute), Philipp Mertins(Helmholtz Association of German Research Centres), Zhong Wu(Nanfang Hospital), Masayuki Watanabe(MANI (Japan)), Jie Bin Liu(Dana-Farber Cancer Institute), J. Alan Diehl(Case Western Reserve University), Steven A. Carr(Broad Institute), Rameen Beroukhim(Broad Institute), Todd Hembrough(OncoPlex Diagnostics (United States)), Jens Puschhof(German Cancer Research Center), Tianxia Li(Columbia University Irving Medical Center), Rachel Rendak(University of Chicago Medical Center), Yu Imamura(Japanese Foundation For Cancer Research), Jin Zhou(The University of Texas Southwestern Medical Center), Eiji Oki(Kyushu University), James M. McFarland(Broad Institute), Austin Dulak(Broad Institute), Steven E. Schumacher(Broad Institute), Les Henderson(University of Chicago Medical Center), Daniel V.T. Catenacci(University of Chicago), Karin Jensen(University of Illinois Urbana-Champaign), Emily O’Day(University of Chicago Medical Center), Hideo Baba(Kaketsuken (Japan)), Xinsen Xu(Dana-Farber Cancer Institute), Peng Xu(Shanxi Medical University), Sarit Schwartz(OncoPlex Diagnostics (United States)), Wei-Li Liao(OncoPlex Diagnostics (United States)), Charles Zou(Dana-Farber Cancer Institute), Annamaria Ruzzo(University of Urbino), Kenichi Nakamura
Nature Medicine
May 24, 2018
Cited by 282


Related Papers